World News Insights
1-3 Minute Gist
Search, personalize, or simply browse. Follow the world around you from gist and context to insights.
Who we are | Our Credo | Ways of using Lyrarc | FAQ | Send Feedback | First Letter From the Editor
Sign up. It's free and easy to use
Create an account
to personalize your feed of articles and topics.
All Topics Article
Generic Drug Makers Facing Squeeze on Revenue
Keywords:
In 2012 40 brand name drugs with sales value of $35 billion lost patent protection. In 2013 this figure falls to $17 billion, according to analysts at Credit Agricole Securities. This means the opportunities for generics makers is diminishing. This is leading to consolidation and specialization by generics makers.
A different patent cliff facing generics drug makers
12/03/2012
Grouped Articles
Generic-Drug Firms Go Beyond Knockoffs
Wall Street Journal 06/15/2013
Generic Drug Makers Facing Squeeze on Revenue
New York Times 12/03/2012
Teva Pharmaceutical financial performance- 2011-2015
05/12/2011
Grouped Articles
Generic-Drug Firms Go Beyond Knockoffs
Wall Street Journal 06/15/2013
Wall Street Journal 10/11/2013
Wall Street Journal 10/31/2013
Mylan Rejects Teva’s $40 Billion Takeover Offer
New York Times 04/27/2015
Teva Poised to Get a Big Boost in Generics
Wall Street Journal 07/27/2015
Wall Street Journal 05/12/2011
Teva acquisitions.
07/26/2005
Grouped Articles
Mylan Rejects Teva’s $40 Billion Takeover Offer
New York Times 04/27/2015
Teva Poised to Get a Big Boost in Generics
Wall Street Journal 07/27/2015
Teva Pharmaceuticals to Buy Allergan’s Generics Business
New York Times 07/27/2015
Teva to Acquire Ivax, Another Maker of Generic Drugs
New York Times 07/26/2005
Teva to Buy U.S. Generic Rival Barr for $7.46 Billion
Wall Street Journal 07/19/2008
Teva Deal Probe Gets Extension
Wall Street Journal 12/03/2008
Mylan
06/15/2005
Grouped Articles
Mylan Proposes to Acquire Rival Perrigo for $28.9 Billion
Wall Street Journal 04/10/2015
Mylan Is Now Big Generics Player After Deal for Unit of Merck KGaA
Wall Street Journal 05/14/2007
Wall Street Journal 06/15/2005
Mylan Rejects Teva’s $40 Billion Takeover Offer
New York Times 04/27/2015
Generic Drug Makers Facing Squeeze on Revenue
New York Times 12/03/2012
Teva Pharmaceutical's strategy
05/12/2011
Grouped Articles
Generic-Drug Firms Go Beyond Knockoffs
Wall Street Journal 06/15/2013
Wall Street Journal 10/11/2013
Wall Street Journal 10/31/2013
Mylan Rejects Teva’s $40 Billion Takeover Offer
New York Times 04/27/2015
Teva Poised to Get a Big Boost in Generics
Wall Street Journal 07/27/2015
Threat of Generic Copycat Comes Back to Nip at Teva
Wall Street Journal 07/25/2011
Indian pharmaceutical manufacturer Ranbaxy performance
03/06/2012
Grouped Articles
Generic-Drug Firms Go Beyond Knockoffs
Wall Street Journal 06/15/2013
Daiichi Sankyo to Sell Troubled Ranbaxy
Wall Street Journal 04/08/2014
India Administers Price-Cap Dose to Drug Companies
Wall Street Journal 09/22/2014
Indiaâs Supreme Court to Hear Dispute on Drug Patents
New York Times 03/06/2012
Generic Drug Makers Facing Squeeze on Revenue
New York Times 12/03/2012
We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.
Support Lyrarc from as small as $1
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us